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AbstrACt
Objectives To evaluate the feasibility of a novel 
multiparametric MRI (mpMRI) and cognitive fusion 
transperineal targeted biopsy (MRTB) led prostate cancer 
(PCa) diagnostic service with regard to cancer detection 
and reducing time to diagnosis and treatment.
Design Consecutive men being investigated for possible 
PCa under the UK 2-week wait guidelines.
setting Tertiary referral centre for PCa in the UK.
Participants Men referred with a raised prostate-specific 
antigen (PSA) or abnormal digital rectal examination 
between February 2015 and March 2016 under the UK 
2-week rule guideline.
Interventions An mpMRI was performed prior to patients 
attending clinic, on the same day. If required, MRTB 
was offered. Results were available within 48 hours and 
discussed at a specialist multidisciplinary team meeting. 
Patients returned for counselling within 7 days
Primary and secondary outcome measures Outcome 
measures in this regard included the time to diagnosis 
and treatment of patients referred with a suspicion of 
PCa. Quality control outcome measures included clinically 
significant and total cancer detection rates.
results 112 men were referred to the service. 111 
(99.1%) underwent mpMRI. Median PSA was 9.4 ng/mL 
(IQR 5.6–21.0). 87 patients had a target on mpMRI with 
25 scoring Likert 3/5 for likelihood of disease, 26 4/5 and 
36 5/5. 57 (51%) patients received a local anaesthetic, 
Magnetic resonance imaging targeted biopsy (MRTB). 
Cancer was detected in 45 (79%). 43 (96%) had University 
College London definition 2 disease or greater. The times 
to diagnosis and treatment were a median of 8 and 20 
days, respectively.
Conclusions This approach greatly reduces the time to 
diagnosis and treatment. Detection rates of significant 
cancer are high. Similar services may be valuable to 
patients with a potential diagnosis of PCa.
IntrODuCtIOn 
Accurate risk stratification for men presenting 
with localised prostate cancer is vitally 
important. In its absence, patient-centred 
management cannot be offered. Men with 
low-risk disease can be safely managed with 
active surveillance, whereas men with a good 
life expectancy and intermediate to high-
risk disease are likely to benefit from inter-
ventional treatment.1 2 Currently, standard 
practice uses prostate-specific antigen (PSA) 
value, digital rectal examination (DRE) 
and transrectal ultrasound guided biopsy 
(TRUSGB). However, TRUSGB is inherently 
random. The tumour cannot be visualised 
with certainty, and thus leads to overdiag-
nosis of insignificant disease in up to 50% 
of men,3 and missing significant disease in 
18% of men, especially if cancer is located in 
the anterior or apical regions of the prostate.4 
This creates difficulty for urologists and adds 
anxiety to patients5 who have to undergo a 
repetitive cascade of diagnostic tests which 
inevitably has cost implications for healthcare 
providers.
Transperineal mapping (TPM) or zonal 
biopsies of the prostate offer a diagnostic 
alternative to TRUSGB with demonstrable 
strengths and limitations of this study
 ► First prospective study demonstrating the clinical 
feasibility of a ‘one stop’, rapid diagnostic prostate 
cancer pathway, using both multiparametric MRI 
(mpMRI) and transperineal targeted biopsy.
 ► Inclusion criteria reflecting ‘real world’ practice in 
the UK.
 ► This study incorporates a standardised mpMRI ac-
quisition and a validated system for defining clini-
cally significant prostate cancer.
 ► Cognitive targeted biopsy performed only, rather 
than mpMRI/ultrasound fusion.
 ► Transperineal, rather than transrectal approach of-
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diagnostic success. However, the burden on patients is 
high. First, the extensive biopsies demand general anaes-
thesia. Second, the rates of urinary retention following 
the procedure are high, making postoperative catheter-
isation commonplace. Third, the large number of cores 
taken requires many hours of labour to assess. Thus, a 
patient may have to wait significantly longer for a result, 
adding to their anxiety. This may also delay necessary 
treatment. Whether this results in adverse outcomes is 
not known. However, all of these established difficulties 
do confer added costs. Indeed, if every patient under-
going TRUSGB instead underwent a TPM, the cost of 
such a move would likely be exceedingly high. Therefore, 
the challenge presents itself as biopsy offering superior 
clinically significant detection rates to the existing stan-
dard, while not conferring an added cost.
Multiparametric MRI (mpMRI) of the prostate has 
proved a useful tool in the diagnosis and risk stratification 
of prostate cancer. MpMRI has demonstrated its ability to 
detect significant cancers, while not detecting those which 
are insignificant.4 Suspicious areas on mpMRI can be 
targeted with subsequent transperineal biopsy (MRTB). 
MRTB has demonstrated greater sampling efficiency and 
accuracy when compared with standard TRUSGB proto-
cols6–8 and has demonstrated accuracy when compared 
with the reference standard of radical prostatectomy 
(RP).9 This allows for a more accurate assessment of 
Gleason grade, and therefore an improved risk stratifica-
tion and treatment plan at diagnosis.10 Furthermore, the 
efficiency advantage, that is, taking fewer cores at biopsy, 
confers significant benefits in cost, patient tolerability 
and postbiopsy sepsis rates.
Three methods of transperineal MRTB currently exist. 
First and most common is ‘cognitive targeting’. This 
approach requires the urologist to review the mpMRI 
images and aim the needle towards the corresponding 
area on ultrasound imaging.11 Alternatively, the reporting 
uroradiologist draws a diagrammatic representation 
of the gland and any suspicious area contained within, 
which guides the urologist to potential cancer. Second, 
‘in-bore MRTB’ is performed while the patient is in the 
MRI scanner, allowing for real-time targeting of suspicious 
areas with MRI-compatible biopsy equipment. Third, 
‘fusion targeting’ uses specifically designed software to 
allow combination of the mpMRI images with real-time 
ultrasound imaging.4 The latter two methods have impli-
cations in terms of equipment availability and cost, and as 
of yet, the question of superiority of any one over another 
remains elusive.4
Currently, prostate cancer diagnostic pathways remain 
built around TRUSGB. MpMRI is more commonly being 
used prior to TRUSGB. However, the use of an mpMRI 
and MRTB pathway remains a rarity despite the potential 
advantages of such an approach and the novel approach 
of both diagnostic interventions in 1 day exceptionally so. 
The reasons for this are multiple and commonly relate to 
the techniques being in their relative infancy. The lack 
of standardised mpMRI reporting,12 a learning curve for 
operators,13 mpMRI availability and cost14 and concern 
regarding missed diagnosis from not sampling the whole 
gland have all been cited as reasons not to accept wide-
spread adoption. Despite this, MRI-guided targeted 
biopsy pathways have been used before, although via the 
transrectal rather than the transperineal route.15–17 The 
recent findings of the PRostate Evaluation for Clinically 
Important disease: Sampling using Image-guidance Or 
Not?  (PRECISION)18 trial has clearly addressed concerns 
with regard to superiority of an MRI-targeted biopsy 
approach over systematic TRUS biopsy, demonstrating 
superiority in clinically significant cancer detection rate 
and a reduction in the detection of insignificant disease.
Thus, the objective of this pilot study was primarily to 
determine the suitability and feasibility of a ‘One-Stop’, 
transperineal MRI-targeted biopsy pathway for prostate 
cancer in ‘real-world’ clinical practice. Outcome measures 
in this regard included the time to diagnosis and treat-
ment of patients referred with a suspicion of prostate 
cancer. Quality control outcome measures included clini-
cally significant and total cancer detection rates.
PAtIents AnD methODs
This prospective study analyses the clinical and service 
outcomes of an mpMRI and MRTB-led prostate cancer 
diagnostic pathway (figure 1) from February 2015 to 
March 2016. Inclusion criteria were men presenting with 
a biochemical or clinical suspicion of prostate cancer 
under the UK 2-week wait programme and undergoing 
mpMRI and if necessary subsequent cognitive targeted 
prostate biopsy. Patients without negative urine cultures or 
with estimated glomerular filtration rates of <30 µmol/L 
were excluded. The patient was contacted on referral, 
and an mpMRI was arranged. This was reported before 
the patient attended clinic in the early afternoon of the 
same day. If a targetable lesion was identified (Likert ≥4), 
a transperineal-targeted biopsy was advised. If a target was 
rated as equivocal (Likert=3), the discussion was more 
nuanced including risk factors for a subsequent biopsy 
being positive such as a positive family history of prostate 
cancer, high PSA density or concordant positive DRE 
findings. Further, in this group of men, those with diffuse 
equivocal changes requiring a greater number of cores to 
be taken for a positive result, the option of full template 
biopsies under general anaesthetic was discussed. Results 
were available within 48 hours and were discussed at a 
specialist multidisciplinary team. Patients returned for 
counselling within 7 days.
MpMRI acquisition was performed according to the 
European guidelines of uroradiology previously described 
by the University College London (UCL) group.12 19 20 In 
summary, this includes the use of a 1.5 or 3.0 Tesla MRI 
scanner acquiring T2-weighted axial and coronal, axial 
diffusion weighted coefficient (DWI) and high b-value, 
as well as T1-weighted dynamic contrast enhancement 
(intravenous Gadolinium) images (DCE). Each scan was 
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described21 22 and a pictorial diagrammatic map drawn 
(figure 2). Regions of interest (ROIs) were scored using 
a Likert-like scale of 1–522 using the overall impression of 
the radiologist to characterise the level of suspicion for 
prostate cancer. ROIs scoring 4 or 5 were thought ‘likely’ 
or ‘highly likely’ to contain a malignant lesion which 
was either ≥0.2 mL in volume and/or had high-grade 
components within (Gleason ≥3+4).23 ROIs 3 were rated 
as indeterminate for such disease and this score of 3, or 
higher, was chosen as the threshold for a positive mpMRI. 
Our choice of scoring system was based on the outcomes 
of the 2011 European Consensus Meeting12 which met 
prior to the Prostate Imaging and Data Reporting System 
(PIRADS) mpMRI reporting consensus meeting19 and 
has demonstrated equivalency with the PIRADS system.24
The procedure was performed as a day case under local 
anaesthesia and antimicrobial prophylaxis in the litho-
tomy position, by either a consultant urologist or urology 
clinical fellow as previously described.25 This biopsy tech-
nique has demonstrated a median procedure length of 
30 min and good patient toleration, with median visual 
analogue pain scores of 1.0.26
Data were collected on a case report form compliant 
with the Standards of Reporting for MRI-targeted Biopsy 
Studies of the prostate.11 Included data were patients 
demographics, indications for biopsy, PSA value, prostate 
volume, number of targets per patient and Likert score per 
target.11 Additionally, for each biopsy collected the total 
number of cores taken, biopsy density, number of posi-
tive cores, maximum and overall Gleason scores and the 
maximum cancer core length (MCCL). Biopsy efficiency 
was calculated by the number of cores demonstrating 
clinically significant disease divided by the number of 
cores taken. For the purpose of this study, clinically signif-
icant disease was defined using the UCL classification for 
interpreting transperineal biopsy findings which sets the 
significance threshold at Gleason score >/=to 3+4 and/
or MCCL ≥4 mm for definition 2 and >/=to 4+3 and/or 
MCCL ≥6 mm for definition 126 (figure 3).
Finally, to assess the time to diagnosis and treatment as 
well as the treatments elected by men were determined by 
examination of the hospital trust’s electronic data system.
Patient and public involvement
Participants were not involved in the design of the study. 
However, conclusions gleaned from the study are to be 
disseminated among patients newly referred to the service.
results
Patient demographics
In total, 112 consecutive biopsy naive men with a median age 
of 68 attended the prostate cancer one stop clinic between 
February 2015 and March 2016 (table 1A). All but one man 
(99%) received an mpMRI scan prior to clinic. The patient 
in question had an MRI incompatible cardiac pacemaker.
mpmrI outcomes
The median prostate volume was 50 mL. Eighty-seven men 
(78%) had a positive mpMRI (Likert score ≥3) and 24 
(22%) had a negative scan (Likert score ≤2) and did not go 
on to biopsy. Twenty-five men (29%) had an mpMRI scan 
Figure 1 The One-Stop mpMRI-led MRTB prostate cancer diagnostic pathway. MDT, multidisciplinary team; mpMRI, 
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with an overall Likert score of 3, 26 (30%) an overall score 
of 4 and 36 (41%) an overall Likert score of 5. There were 
162 ROIs identified on mpMRI with a median volume of 
0.5 mL when measured on T2 MRI sequencing. Thirty-nine 
men (45%) had a single ROI on mpMRI, 25 men (29%) 
had two, 22 men (25%) had three and a single man (1%) 
had four. Seventy-one lesions (30%) were Likert 3, 49 (30%) 
were Likert 4 and 42 (26%) were Likert 5. After mpMRI, 
nine with negative mpMRIs (38%) were discharged for PSA 
surveillance in the community, 10 (42%) remained on PSA 
surveillance in secondary care, four (17%) underwent inves-
tigations for lower urinary tract symptoms and one (4%) 
underwent a full template biopsy under general anaesthetic 
(table 1B).
biopsy outcomes
Fifty-seven men (51%) underwent a local anaesthetic MRTB 
as described following mpMRI (table 1C). Fifteen (17%) 
men chose not to undergo biopsy under local anaesthetic 
and were listed for a biopsy under sedation. Thirteen men 
(15%) did not have a biopsy due to clinical reasons. Any 
cancer was detected in 45 (79%) men. Of these, 43 (96%) 
satisfied the UCL 2 criteria for clinical significance and 34 
(76%) satisfying the UCL 1 criteria. The median MCCL of 
positive biopsies was 7 mm. The calculated biopsy efficiency 
for UCL 2 disease was 47%. The median number of cores 
taken per ROI was 4, with a median calculated biopsy density 
of 10 cores/mL of ROI. Of the 20 men who had more than 
one lesion on mpMRI and underwent biopsy, two had a 
secondary lesion which harboured either higher grade or 
volume disease. In only one of these men was the secondary 
lesion a lower Likert score. Both such men went on to RP.
Diagnosis and treatment outcomes
The median time to a man being told his diagnosis was 
8 days, and the median time by which treatment had 
been started was 20 days, although in five cases this time 
period was not clear (table 1D). The treatment outcomes 
are shown in table 1D. Of note, 20 (18%) men were 
discharged after biopsy with 19 (17%) men starting PSA 
surveillance. Forty-four (40%) went on to undergo treat-
ment, and nine (8%) men underwent a further biopsy 
either due to a perceived false negative or diffuse disease 
requiring a biopsy under sedation or general anaesthetic. 
Eleven (10%) patients underwent further assessment or 
treatment for benign disease.
DIsCussIOn
An optimal prostate cancer diagnostic strategy should encap-
sulate maximal significant cancer detection while avoiding 
insignificant disease or repeat biopsy. Furthermore, it should 
convey enough information for urologists and patients to 
accurately devise a treatment plan according to the risk of 
Figure 2 A pictorial prostate mpMRI diagrammatic report, as drawn by the uroradiologist. mpMRI, multiparametric MRI; SV, 
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progression. However, as things stand, the diagnostic pathway 
is still commonly led by TRUSGB, despite its accepted inac-
curacy, especially for disease located in the anterior or apical 
regions of the prostate.27 In particular the negative predictive 
value (NPV) of the originally described six core TRUSGB 
is poor, with false-negative rates of around 35%.28 29 This 
inherent disadvantage is somewhat mitigated by extending 
the biopsy to a 12-core or even 24-core technique, however 
increasing the number of cores past 12 leads to increased 
numbers of insignificant cancers being detected30 31 which is 
present in 40% of men over the age of 50.32 These cancers 
rarely affect life expectancy or its quality in any meaningful 
way and revealing them simply adds unnecessary burdens 
to patients. Furthermore, increasing the number of cores 
may increase incidence of post-TRUSGB sepsis33 and with 
the incidence already on the rise alongside increasing preva-
lence of colonisation with resistant organisms such strategies 
pose an increasing potential for harm34 for which our clin-
ical options are worryingly limited. As a result, transperineal 
mapping (TPM) zonal or mapping biopsies have become 
more popular. In particular, one recent series reported a 0% 
readmission rate for infective complications after targeted 
transperineal biopsy,35 in comparison with rates of sepsis of 
up to 6.3% after TRUSGB.36 However, there are significant 
Figure 3 The University College London (UCL) ‘traffic light 
like’ system to define significant prostate cancer.
Table 1 (A) Baseline demographics for the cohort, (B) 
mpMRI outcomes, (C) biopsy outcomes and (D) diagnosis 
and treatment outcomes 
A. Patient demographics
Men included 112
Median age (years) 68 (IQR 62–78)
Median PSA (ng/mL) 9.4 (IQR 5.6–21.0)
B. MpMRI outcomes n %
Men undertaking mpMRI 111 99
Median prostate volume (mL) 50 (IQR 35–78)
Positive mpMRI (men) 87 78
Negative mpMRI (men) 24 22
Total ROIs 162
1. ROIs/man 39 35
2. ROIs/man 25 23
3. ROIs/man 22 20
4. ROIs/man 1 1
Likert score per man
  Likert 3 25 23
  Likert 4 26 23
  Likert 5 36 32
Total ROIs 162
Median ROI volume (mL) 0.5 (IQR 0.2–1.0)
Likert score per lesion
  Likert 3 71 44
  Likert 4 49 30
  Likert 5 42 26
C. Biopsy outcomes n %
Men undertaking biopsy 57 51
Median cores per patient 9 (IQR 5–12)
Total cores 514
Cores positive (UCL 2) 241 47
Biopsy efficiency 47%
Median cores per lesion 4 (IQR 4–5)
Median biopsy density 
(cores/ROI mL) 10 (IQR 3.5–20)
Cancer detection by man
  Any cancer 45 79
  UCL 2 43 75
  UCL 1 34 60
  Gleason ≥3+4 43 75
  Gleason ≥4+3 23 40
  Median MCCL (mm) 7 (IQR 3–10)
Cancer detection by lesion Any cancer UCL 2 UCL 1
  Likert 3 (lesions biopsied) 40 13 10 4
  Likert 4 (lesions biopsied) 38 24 19 15
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concerns regarding its cost, need for general anaesthetic, 
increased complications and patient burden. Such concerns 
have justly prevented its wider use and certainly a TPM-led 
diagnostic pathway has not been seriously suggested.
However, the development and refinement of mpMRI 
demands that its use in leading an approach to diagnosis 
must be contemplated. MpMRI has demonstrated high 
levels of accuracy for the detection of clinically significant 
cancer when compared with both TPM37 and whole-mount 
prostatectomy specimens.9 Indeed, a systematic review by 
Fütterer et al found that mpMRI detected clinically signifi-
cant disease in up to 84% of men with an NPV of up to 98% 
where either TPM or prostatectomy was used as the refer-
ence standard.20 More recently, the results of the Prostate 
MR Imaging Study (PROMIS) trial demonstrate the sensi-
tivity and NPV of mpMRI in detecting clinically significant 
disease as 93% and 89%, respectively.38 Furthermore, the 
PROMIS trial demonstrated that 27% of men could avoid a 
biopsy.38 Despite these findings, both the European Associa-
tion of Urology39 and the National Institute for Health and 
Care Excellence40 still do not recommend mpMRI prior to 
an initial set of biopsies. In this study, leading with mpMRI 
allowed 24 (21.6%) men to avoid a biopsy entirely. However, 
the majority would remain on PSA surveillance due to the 
small—but understood—risk of a false-negative mpMRI. 
There is perhaps a concern that in less-experienced centres, 
overcall of images as PIRADS 3 is an issue that will expose 
men to unnecessary biopsies, thus reducing the benefit of 
an image-guided pathway. However, as the PIRADS V.241 
scoring system is increasingly adopted, with its ability to 
define a PIRADS 4 lesion over a 3 by utilisation of the second 
parameter (Dynamic contrast enhanced (DCE) and Diffu-
sion-weighted imaging (DWI) for peripheral zone and tran-
sition zone lesions, respectively), alongside its more easily 
understood and applicable design, should reduce such an 
effect going forward.
Clearly, there is enough evidence now to introduce an 
image-guided biopsy to the prostate cancer diagnostic 
pathway, bringing it in line with the current practice in 
other solid organ malignancies. However, currently there 
is concern that targeted biopsies alone risk missing areas of 
significant disease that appear normal on mpMRI. This may 
be viewed as a limitation. However, our current approach 
to this cohort of men was introduced after our paired anal-
yses of mpMRI versus template biopsies demonstrated that 
mpMRI cognitive biopsies had equivalent detection rates to 
zonal mapping biopsies.37 Furthermore, numerous centres 
have now reported improved cancer detection rates of MRTB 
strategies when compared with systematic approaches,6 42 as 
well as improved biopsy efficiency and reduced false-negative 
rates for significant cancer.8 To underline this, another series 
of men who underwent both fusion MRTB and systematic 
TPM showed a difference of clinically significant cancer-de-
tection rates of 4% (28% for MRTB and 24% for systematic 
biopsy), although combined biopsies outperformed each 
approach in isolation.43 Naturally, such results have been 
reported by specialist centres and as such, concern remains 
with regard to the level of operator dependency with 
targeted biopsy techniques. However, authors have found 
no difference between cancer detection rates with targeted 
techniques regardless of the experience of the operator, 
although with TRUSGB.44 Of course, advocating for a rapid 
uptake of such techniques in centres with no prior experi-
ence would be optimistic. Instead, we envisage a stepwise, 
quality-controlled uptake of transperineal approach biopsies 
and mpMRI reporting before adopting targeted strategies.
As with mpMRI, MRTB is not a perfect test, both can miss 
significant disease. However, this is an improvement on 
our current standard diagnostic test which is demonstrably 
poor.27–30 As recent studies have shown, in comparison with 
TRUSGB, MRTB is more likely to detect disease once a suspi-
cious area has been identified.6 17 Furthermore, the recently 
published PRECISION randomised controlled trial clearly 
demonstrated the superior clinically significant cancer 
detection rate of MRTB and a reduced insignificant cancer 
detection rate when compared with systematic TRUSGB.18
A potential limitation of the MRTB technique in this 
study is the use of ‘cognitive fusion’ rather than ultra-
sound/mpMRI fusion or ‘in-bore’ targeting. However, no 
superiority of one technique over another has been clearly 
demonstrated, while ‘cognitive fusion’ is clearly a less costly 
option.45 Another potential limitation of the targeted biopsy 
strategy is the ‘satisfaction of search’ bias. Essentially, this 
means that after the primary lesion is scored, less attention 
to detail is given to subsequent lesions which may therefore 
be undercalled or undersampled. However, in this series this 
occurred twice, only once where the secondary lesion was 
attributed a lower score than the primary, and in no cases 
did this change the proposed management. Further, in the 
vast majority of centres where radical treatments—rather 
than focal—remain the standard of care, there would likely 
be no change in the approach to curative therapy, save for 
D. Diagnosis and treatment outcomes
Median time to diagnosis (days) 8 (IQR 5–12)
Median time to treatment (days) 20 (IQR 8–40)
Treatment type (postbiopsy) n %
Discharged 4 7
PSA surveillance 6 11
Active surveillance 5 9
Focal therapy 6 11
Robotic prostatectomy 9 16
External beam radiotherapy 10 18
Brachytherapy 2 4
Androgen deprivation therapy 9 16
Chemotherapy 4 7
Antibiotics 1 2
Repeat biopsy 1 2
MCCL, maximum cancer core length; mpMRI, multiparametric 
MRI; PSA, prostate-specific antigen; ROI, regions of interest; UCL, 
University College London.
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planning for prostatectomy in the case of nerve-sparing 
procedures.
The cost of mpMRI has been cited as a reason for persisting 
with TRUSGB-led diagnostic pathways,46 using it instead 
for a second investigation in the case of a negative biopsy 
in a patient in whom suspicion of cancer remains. While 
mpMRI is indeed useful in this scenario, recent cost-effec-
tiveness analyses have shown the long-term cost–benefits of 
mpMRI-led pathways when various outcomes are accounted 
for14 47 48 due to a reduction in overdiagnosis and higher 
detection rates of clinically significant disease at primary 
biopsy. In particular, the cost analysis of the PROMIS trial 
cohort demonstrated that MpMRI first followed by two 
MRTBs detects more cancer per pound spent than a TRUS-
first biopsy strategy.48
A major advantage of our pathway is the low time to diag-
nosis and treatment. At a median of 8 and 20 days, respec-
tively, the time a patient waits is significantly below the 31-day 
and 62-day targets set by the UK National Health Service. The 
meeting of these targets is a persistent challenge nationally.49 
Moreover, performing an mpMRI prior to primary biopsy 
negates the risk of an initial false-negative biopsy significantly 
delaying a subsequent mpMRI due to postbiopsy haemor-
rhage within the prostate. This makes it difficult to localise 
cancer or accurately determine its size or border.50 In such 
circumstances, the delay in diagnosis can be up to 8 weeks.
COnClusIOns
This novel pathway offers an alternative to standard prostate 
cancer diagnostic services. Attendance and cancer detection 
rates are high. The use of an mpMRI led pathway allows for a 
significant proportion of men to avoid a biopsy and for those 
who do, the time to diagnosis and definitive treatment is kept 
particularly low. The integration of both mpMRI and MRTB 
in the prostate cancer diagnostic pathway has shown cost-ef-
fectiveness in the long term. This is especially true where 
rapid diagnostics are mandated or desirable. Furthermore, 
today, where septic complications are of grave concern, the 
transperineal route is particularly advantageous. This pilot 
study demonstrates that similar services can be provided in 
appropriate centres and may be valuable to patients with a 
potential diagnosis of prostate cancer.
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